News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sankyo Pharma GmbH Simplifying Clinical Trial Communications With IntraLinks, Inc.; Pharma Leader To Manage Document Flow For ROADMAP Trial In More Than 22 European Countries


10/19/2005 5:09:53 PM

IntraLinks, the leading pharmaceutical industry provider of secure document exchange technology, announced today that Sankyo Pharma GmbH will use its secure online workspaces to manage document flow for its ROADMAP (Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention) clinical trial. This study will involve 22 countries and about 220 centres throughout Western and Eastern Europe, and will recruit more than 4,400 patients. ROADMAP is the first ever large-scale multinational trial to study whether the compound Olmesartan, the latest Angiotensin II Receptor Blocker (ARB), can prevent the onset of microalbuminuria -- an early sign of kidney disease -- in patients with type 2 diabetes.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES